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Background
The assessment of HIV neutralization using peripheral
blood mononuclear cells (PBMC) is a complex process,
attributable to numerous variables. Here we measure both
intra- and inter-assay variability in a PBMC neutralization
assay, and assess the variation contributed by the PBMC
source for both virus propagation and assay targets, in
efforts to inform modifications required for assay stand-
ardization.
Methods
Primary isolates or infectious molecular clones (IMC)
were propagated in PBMC from multiple donors (or were
293T cell-derived); neutralization profiles were assessed
using different target cells. Cell line targets were used to
further assess the influence of virus source, and reporter
IMCs tested assay design and endpoint variation. The end-
points were p24 production or Renilla luciferase expres-
sion; IC50 ranges were compared to determine intra- and
inter-assay variability.
Results
Intra-assay variation (between operators using the same
reagents) was independent of reagents used and averaged
2.2-fold (N = 253 assays, excluding concordant negative
results). Altering the source of PBMC targets induced
inter-assay variability that was neutralization reagent-spe-
cific, and occurred even when 293T-derived virus was
used. The greatest differences were observed with 2G12
(194-fold range in IC50s) and ten-fold less variation was
observed using sCD4 (11-fold maximum range). The var-
iability resulting from using different targets was not
reduced by employing novel, luciferase-expressing IMC.
Varying the PBMC source for viral propagation also
induced inter-assay variation, and viral strains behaved
differently. Using reporter cell line targets with virus pro-
duced in different PBMC limited inter-assay differences to
that of intra-assay variation.
Conclusion
Variability in the PBMC neutralization assay is influenced
by the PBMC source and multiple variables. While use of
reporter cell targets reduced neutralization assay variabil-
ity, novel reporter IMCs reduce PBMC assay workload but
not the variability related to donor differences. Further
analysis of host genetic properties will facilitate identifica-
tion of specific characteristics that significantly influence
neutralization profiles.
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